-
Cracker Barrel Appoints New CFO - Analyst Blog
Friday, December 17, 2010 - 11:15am | 416Lebanon, Tenn-based Cracker Barrel Old Country Store Inc. (CBRL) has finally found a replacement for its previous chief financial officer (CFO) Sandra B. Cochran. The company recently announced the appointment of former O'Charley's Inc.'s (CHUX) CFO and treasurer Lawrence E. Hyatt as its CFO and...
-
Morgan Keegan Raises HAE Target From $65 To $70
Friday, December 17, 2010 - 7:55am | 21Morgan Keegan is raising its PT on Haemonetics Corporation (NYSE: HAE) from $65 to $70.
-
West Announces Dividend of $.17
Thursday, December 16, 2010 - 5:29pm | 45West Pharmaceutical Services, Inc. (NYSE: WST) today announced that its Board of Directors has approved payment of the first-quarter 2011 cash dividend of $0.17 per share. The dividend will be paid on February 2, 2011 to shareholders of record on January 19, 2011.
-
Novartis to Wrap Up Alcon Buy - Analyst Blog
Thursday, December 16, 2010 - 1:24pm | 617Alcon Inc. (ACL) recently announced that its board of directors has given the nod for its merger with Novartis AG (NVS). Novartis plans to pay $168 per share to acquire the remaining 23% share of Alcon it does not already own. Per the terms of the agreement, the merger consideration will consist...
-
Novartis to Wrap Up Alcon Buy - Analyst Blog
Thursday, December 16, 2010 - 1:00pm | 617Alcon Inc. (ACL) recently announced that its board of directors has given the nod for its merger with Novartis AG (NVS). Novartis plans to pay $168 per share to acquire the remaining 23% share of Alcon it does not already own. Per the terms of the agreement, the merger consideration will consist...
-
Immucor Upgraded to Neutral - Analyst Blog
Thursday, December 16, 2010 - 12:03pm | 494Recently, we upgraded Immucor (BLUD) to Neutral with a target price of $21.00. Immucor had begun fiscal 2011 on a disappointing note amidst lower demand for both reagents and instruments on the back of economic uncertainty. Tighter hospital budgets and uncertainty in the healthcare market have...
-
Immucor Upgraded to Neutral - Analyst Blog
Thursday, December 16, 2010 - 11:45am | 494Recently, we upgraded Immucor (BLUD) to Neutral with a target price of $21.00. Immucor had begun fiscal 2011 on a disappointing note amidst lower demand for both reagents and instruments on the back of economic uncertainty. Tighter hospital budgets and uncertainty in the healthcare market have...
-
Stock Market News for Dec 16, 2010 - Market News
Thursday, December 16, 2010 - 10:33am | 905A late-day sell-off, for the third consecutive day, witnessed the markets go slightly lower on Wednesday. On a lackluster day of major events that could negatively impact the indices, markets were partially affected by a rise in Treasury yields. Euro-zone debt crisis re-surfaced concerns among...
-
Stock Market News for Dec 16, 2010 - Market News
Thursday, December 16, 2010 - 10:06am | 905A late-day sell-off, for the third consecutive day, witnessed the markets go slightly lower on Wednesday. On a lackluster day of major events that could negatively impact the indices, markets were partially affected by a rise in Treasury yields. Euro-zone debt crisis re-surfaced concerns among...
-
Haemonetics Stays Neutral - Analyst Blog
Wednesday, December 15, 2010 - 6:03pm | 430Recently, we reiterated our Neutral recommendation on Haemonetics Corporation (HAE) with a target price of $67.00. Haemonetics reported adjusted EPS of 80 cents in the second quarter of fiscal 2011, surpassing the Zacks Consensus Estimate by 4 cents. The adjusted EPS was 16% higher than the...
-
Haemonetics Stays Neutral - Analyst Blog
Wednesday, December 15, 2010 - 5:28pm | 430Recently, we reiterated our Neutral recommendation on Haemonetics Corporation (HAE) with a target price of $67.00. Haemonetics reported adjusted EPS of 80 cents in the second quarter of fiscal 2011, surpassing the Zacks Consensus Estimate by 4 cents. The adjusted EPS was 16% higher than the...
-
Large Cap Winners & Losers (NVS, CAT, HDB, FBR)
Wednesday, December 15, 2010 - 2:43pm | 320The broader markets are solidly negative, but despite this, there are some large cap stocks that are outperforming today, for a variety of reasons. There are also a handful of stocks that are being hit sharply. Novartis (NYSE: NVS) is up around 5% on news that the company is completing its...
-
Novartis' Zometa Disappoints - Analyst Blog
Wednesday, December 15, 2010 - 1:00pm | 490Recently, Novartis AG (NVS) presented data from the AZURE trial of its bone drug Zometa at the annual Antonio Breast Cancer Symposium. The phase III study tested the effectiveness of Zometa in improving disease free survival in both premenopausal and postmenopausal women with early breast cancer...
-
Novartis' Zometa Disappoints - Analyst Blog
Wednesday, December 15, 2010 - 12:45pm | 490Recently, Novartis AG (NVS) presented data from the AZURE trial of its bone drug Zometa at the annual Antonio Breast Cancer Symposium. The phase III study tested the effectiveness of Zometa in improving disease free survival in both premenopausal and postmenopausal women with early breast cancer...
-
Company News for December 15, 2010 - Corporate Summary
Wednesday, December 15, 2010 - 11:33am | 638• Joy Global (NASDAQ:JOYG) reported fiscal fourth quarter earnings of $1.39, ahead of the Zacks Consensus Estimate of $1.16, on revenues of $1.05 billion that topped the Zacks Consensus Estimate of $925.0 million. The firm provided upside 2011 guidance of $5.00-$5.30, above the Zacks Consensus...